Lena Friberg
Uppsala Universitet
H-index: 54
Europe-Sweden
Top articles of Lena Friberg
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Synergy of polymyxin B and minocycline against KPC-3-and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions | Journal of Antimicrobial Chemotherapy | Anna Olsson Christer Malmberg Chenyan Zhao Lena E Friberg Elisabet I Nielsen | 2024/2 |
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis | Clinical Pharmacokinetics | Maddalena Centanni Mirjam E van de Velde Aniek Uittenboogaard Gertjan JL Kaspers Mats O Karlsson | 2024/2 |
Multistate modeling for survival analysis in critically ill patients treated with meropenem | CPT: Pharmacometrics & Systems Pharmacology | Yaru Peng Iris K Minichmayr Han Liu Feifan Xie Lena E Friberg | 2024/2 |
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia | Leukemia | Merete Dam Maddalena Centanni Lena E Friberg Daniel Centanni Mats O Karlsson | 2024/1/29 |
Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis | Clinical Pharmacology & Therapeutics | Anders Thorsted Chiara Zecchin Alienor Berges Mats O Karlsson Lena E Friberg | 2024/3/19 |
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib | CPT: Pharmacometrics & Systems Pharmacology | Anyue Yin GD Marijn Veerman Johan GC van Hasselt Christi MJ Steendam Hendrikus Jan Dubbink | 2024/2/20 |
Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model | International Immunopharmacology | Eman IK Ibrahim Espen B Ellingsen Sara M Mangsbo Lena E Friberg | 2024/1/5 |
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children | Maddalena Centanni David Elhad Omar Zaher Mats O Karlsson Lena E Friberg | 2023/12/8 | |
Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models | CPT: Pharmacometrics & Systems Pharmacology | Eman IK Ibrahim Mats O Karlsson Lena E Friberg | 2023/9 |
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and … | CPT: Pharmacometrics & Systems Pharmacology | Robin J Svensson Qing Xi Ooi Lena E Friberg Narendra Maharaj Pramod Kumar Reddy | 2023/2 |
Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies | CPT: Pharmacometrics & Systems Pharmacology | Anders Thorsted Anh Duc Pham Lena E Friberg Elisabet I Nielsen | 2023/12 |
Prevalence and clinical consequences of colistin heteroresistance and evolution into full resistance in carbapenem-resistant Acinetobacter baumannii | Microbiology Spectrum | Hadas Kon Amichay Hameir Amir Nutman Elizabeth Temkin Alona Keren Paz | 2023/6/15 |
Thanks to our Reviewers of 2022! | Journal of Pharmacokinetics and Pharmacodynamics | Leon Aarons Felix Agbo Karel Allegaert Teodor M Atanackovic Rebecca Baillie | 2023 |
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1 | The AAPS journal | Javier Sánchez Valeria Nicolini Linda Fahrni Inja Waldhauer Antje-Christine Walz | 2023/4/1 |
A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology | CPT: Pharmacometrics & Systems Pharmacology | Javier Sánchez Christina Claus Rosmarie Albrecht Brenda C Gaillard Joana Marinho | 2023/11 |
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors | Clinical and Translational Science | Maddalena Centanni Abel Thijs Ingrid Desar Mats O Karlsson Lena E Friberg | 2023/1 |
Multistate pharmacometric model to define the impact of second‐line immunotherapies on the survival outcome of the IMpower131 study | Clinical Pharmacology & Therapeutics | Sreenath M Krishnan Lena E Friberg François Mercier Rong Zhang Ben Wu | 2023/4 |
A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer | CPT: Pharmacometrics & Systems Pharmacology | Han Liu Ana‐Marija Milenković‐Grišić Sreenath M Krishnan Siv Jönsson Lena E Friberg | 2023/11 |
Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli | Cytokine | Salma M Bahnasawy Paul Skorup Katja Hanslin Miklós Lipcsey Lena E Friberg | 2023/9/1 |
Data from Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework | Ida Netterberg Mats O Karlsson Leon WMM Terstappen Miriam Koopman Cornelis JA Punt | 2023/3/31 |
